You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,546,409


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,546,409
Title:Methods of treatment for solid tumors
Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula I, ##STR00001## or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient.
Inventor(s): Puri; Kamal D. (Lynnwood, WA), Evarts; Jerry B. (Foster City, CA), Lannutti; Brian (Seattle, WA), Giese; Neill (Seattle, WA)
Assignee: Gilead Calistoga LLC (Foster City, CA)
Application Number:12/763,991
Patent Claims:1. A method of treating a solid tumor in a subject comprising administering to said subject an optically active compound of formula I ##STR00007## or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an optically active compound of formula I or a pharmaceutically acceptable salt thereof; wherein the amount of the optically active compound of formula I or a pharmaceutically acceptable salt thereof is an amount effective to treat the solid tumor.

2. The method of claim 1, wherein the solid tumor is selected from the group consisting of pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer, and soft tissue sarcoma.

3. The method of claim 1, wherein the solid tumor is selected from non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.

4. The method of claim 1, wherein the pharmaceutical composition comprises the optically active compound of formula I and the corresponding R-enantiomer of the optically active compound of formula I, or pharmaceutically acceptable salts thereof, and wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof predominates over the corresponding R-enantiomer of the optically active compound of formula I or pharmaceutically acceptable salt thereof by a ratio of at least about 9:1.

5. The method of claim 1, wherein the pharmaceutical composition comprises the optically active compound of formula I and the corresponding R-enantiomer of the optically active compound of formula I, or pharmaceutically acceptable salts thereof, and wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof predominates over the corresponding R-enantiomer of the optically active compound of formula I or pharmaceutically acceptable salt thereof by a ratio of at least about 19:1.

6. The method of claim 1, wherein the optically active compound, or pharmaceutically acceptable salt thereof, or pharmaceutical composition is administered orally.

7. The method of claim 1, wherein the optically active compound of formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition is administered in solid form.

8. The method of claim 7, wherein the solid form comprises the optically active compound of formula I or pharmaceutically acceptable salt thereof admixed with at least one pharmaceutically acceptable excipient.

9. The method of claim 7, wherein the solid tumor is ovarian, renal, breast, lung, colon or prostate cancer.

10. The method of claim 1, wherein the subject is refractory to chemotherapy treatment, or in relapse after treatment with chemotherapy.

11. The method of claim 1, wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof is administered at a dose of 20-500 mg/day.

12. The method of claim 1, wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof is administered at a dose of 50-250 mg/day.

13. The method of claim 1, wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof is administered at a dose of 50-150 mg twice per day.

14. The method of claim 1, wherein the optically active compound of formula I or pharmaceutically acceptable salt thereof is administered at least twice daily.

15. The method of claim 1, wherein the subject is a human subject.

16. The method of claim 15, wherein the concentration of the optically active compound of formula I or pharmaceutically acceptable salt thereof in the subject's blood is between 40-3000 ng/mL over a 12 hour period from the time of administration.

17. The method of claim 15, wherein the concentration of the optically active compound or pharmaceutically acceptable salt thereof in the subject's blood is between about 100 nM and 2000 nM.

18. The method of claim 1, wherein the optically active compound of formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition is administered to the subject orally, intravenously or by inhalation.

19. The method of claim 1, further comprising administering in addition to the optically active compound of formula I or pharmaceutically acceptable salt thereof to said subject, a therapeutically effective amount of at least one therapeutic agent and/or therapeutic procedure to treat said solid tumor in said subject.

20. The method of claim 19, wherein said therapeutic agent is selected from the group consisting of an EGFR inhibitor, an mTOR inhibitor, a platin, and a taxane.

21. The method of claim 19, wherein said therapeutic procedure is selected from the group consisting of peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, immunohistochemistry staining method, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, high-dose chemotherapy and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

22. The method of claim 1 further comprising obtaining a biological sample from said subject; and analyzing said biological sample with an analytical procedure selected from the group consisting of blood chemistry analysis, chromosomal translocation analysis, needle biopsy, fluorescence in situ hybridization, laboratory biomarker analysis, immunohistochemistry staining method, flow cytometry or a combination thereof.

23. The method of claim 22, wherein the optically active compound of formula I, or pharmaceutically acceptable salt thereof, or pharmaceutical composition is administered twice daily for about 28 days, and is then discontinued for at least 7 days.

24. The method of claim 19, wherein said therapeutic agent is selected from the following group consisting of docetaxel, mitoxantrone, prednisone, estramustine, anthracyclines, taxanes, cyclophosphamide, capecitabine, 5-fluorouracil, gemcitabine, methotrexate, vinorelbine, an EGFR inhibitor, trastuzumab, bevacizumab, platins, temazolamide, interferon alpha, and IL-2.

25. The method of claim 19, wherein said therapeutic agent is selected from the following group consisting of docetaxel, mitoxantrone, prednisone, estramustine, doxorubicin, epirubicin, liposomal doxorubicin, paclitaxel, and protein-bound paclitaxel, cyclophosphamide, capecitabine, 5-fluorouracil, gemcitabine, methotrexate, vinorelbine, erlotinib, trastuzumab, bevacizumab, cisplatin, carboplatin, temazolamide, interferon alpha, and IL-2.

Details for Patent 8,546,409

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-04-20
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2029-04-20
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2029-04-20
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2029-04-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.